Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00072839 |
Recruitment Status :
Completed
First Posted : November 13, 2003
Last Update Posted : May 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn's Disease | Drug: ALX-0600 Drug: placebo Drug: teduglutide 0.05 Drug: teduglutide 0.2 mg Drug: Teduglutide 0.05 dose Drug: teduglutide 0.1 mg dose | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease |
Actual Study Start Date : | November 12, 2003 |
Actual Primary Completion Date : | July 28, 2005 |
Actual Study Completion Date : | July 28, 2005 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
placebo solution injected subcutaneously daily into either thigh or abdomen.
|
Drug: placebo
placebo solution injected subcutaneously |
Experimental: teduglutide 0.05
teduglutide 0.05 mg/kg/d injected subcutaneously daily.
|
Drug: Teduglutide 0.05 dose
0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
Other Name: GATTEX |
Experimental: teduglutide 0.1
0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
|
Drug: teduglutide 0.1 mg dose
0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Other Name: GATTEX |
Experimental: teduglutide
0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
|
Drug: ALX-0600
teduglutide
Other Name: GATTEX Drug: teduglutide 0.05 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
Other Name: GATTEX Drug: teduglutide 0.2 mg 0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Other Name: GATTEX |
- The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8. [ Time Frame: 8 weeks of treatment ]
- The various secondary efficacy variables are based on the CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ), plasma citrulline and laboratory inflammatory markers. [ Time Frame: 8 weeks of treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Men and women, 18 years of age and older
- Signed and dated informed consent to participate before any study-related procedures are performed
- Diagnosis of Crohn's disease for at least 6 months that has been documented and confirmed
- A Crohn's Disease Activity Index (CDAI) score of 220 to 450 inclusive
- Female subjects who are not surgically sterile or postmenopausal must use medically acceptable methods of birth control during and for 30 days after the treatment period.
- HCT 30% or greater
- WBC 3.5 x 109/L or greater
- Platelets 100 x 109/L or greater
- Adequate renal function defined as: serum creatinine and BUN 1.5 x ULN or less
- Adequate hepatic function defined as: ALT/SPGT, AST/SGOT 2.0 x ULN or less; total bilirubin 1.25 x ULN or less, alkaline phosphatase 1.5 x ULN or less
- Female subjects of childbearing potential must have negative urine pregnancy test results prior to randomization
- A stool sample must be taken at screening and analyzed by a local laboratory for enteric pathogens, pathogenic ova and parasites, and Clostridium difficile toxin, and reported negative prior to randomization.
- C-reactive protein value must be 1.0 mg/dL or more, unless there are obvious manifestations of currently active Crohn's disease such as positive observations on endoscopy, other positive indications by laboratory test results, or the subject has had a previous intestinal resection for Crohn's disease.
Exclusion Criteria
- Nutritionally compromised subjects requiring enteral or parenteral therapy to maintain weight
- Body weight less than 40 kg or more than 100 kg
- Bowel obstruction or any condition that may predispose to its development, intestinal perforation, or significant gastrointestinal hemorrhage
- Current ileostomy or colostomy or extensive external fistulization (more than 3 external fistulae which are expressible with gentle compression)
- Expected to require surgical therapy for Crohn's disease or Crohn's disease related complications within 12 weeks of screening. If an abscess is present, it should be drained at least 3 weeks before pre-screening
- History of ulcerative colitis within 6 months of screening visit
- Cushing's syndrome
- Known HIV infection, or symptoms or signs of HIV infection
- Acute systemic infection and/or intestinal infection requiring antibiotic therapy at time of screening or baseline
- Evidence of chronic hepatitis B or C viral infection
- Decompensated liver disease
- Clinically significant ECG abnormalities
- History of angina or cardiac arrhythmia requiring drug or device intervention or clinically significant congestive heart failure or other clinically significant cardiac disease
- History of myocardial infarction within 12 months of screening
- History of thromboembolic disease (e.g., phlebitis, pulmonary embolus) or known congenitally or acquired prothrombotic disorder (e.g., protein C deficiency)
- History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
- Known substance abuse in the previous 2 years
- Nursing mothers or pregnant women
- Use of native GLP-2, growth hormone, or growth factors within 3 months of signing informed consent
- Use of any of the prior or concomitant medications described in section 5.4, except as specified
- Known hypersensitivity to any of the active or inactive constituents of ALX-0600

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00072839

Study Director: | Study Director | Takeda |
Responsible Party: | Shire |
ClinicalTrials.gov Identifier: | NCT00072839 |
Other Study ID Numbers: |
CL0600-008 |
First Posted: | November 13, 2003 Key Record Dates |
Last Update Posted: | May 25, 2021 |
Last Verified: | May 2021 |
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |
Teduglutide Gastrointestinal Agents Radiation-Protective Agents Protective Agents Physiological Effects of Drugs |